Pharmacologic Treatments for PCOS Patients. [Review]

MedStar author(s):
Citation: Clinical Obstetrics & Gynecology. 64(1):55-64, 2021 03 01.PMID: 33346594Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Infertility, Female | *Polycystic Ovary Syndrome | Adult | Female | Humans | Infertility, Female/dt [Drug Therapy] | Infertility, Female/et [Etiology] | Life Style | Menstruation Disturbances | Polycystic Ovary Syndrome/dt [Drug Therapy]Year: 2021Local holdings: Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003ISSN:
  • 0009-9201
Name of journal: Clinical obstetrics and gynecologyAbstract: Polycystic ovarian syndrome is the most common endocrinopathy in reproductive-aged women and has a vast array of clinical manifestations. Common clinical presentations of the disorder include anovulatory infertility, menstrual disorders, cutaneous symptoms secondary to androgen excess, metabolic abnormalities and mental health issues. If the condition is left unaddressed or inadequately treated, long-term sequelae such as endometrial hyperplasia, diabetes mellitus and dyslipidemia may ensue, therefore it is imperative for clinicians to address each component of the syndrome. When initial lifestyle changes and dietary modifications do not suffice or fail, pharmacologic therapy should be considered, and when deemed appropriate treatment should be initiated. This review describes the pharmacologic options available to combat the various sequelae commonly seen in women with polycystic ovarian syndrome. Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.All authors: Kodama S, Torrealday SOriginally published: Clinical Obstetrics & Gynecology. Publish Ahead of Print, 2020 Dec 18.Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2020-12-31
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33346594 Available 33346594

Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003

Polycystic ovarian syndrome is the most common endocrinopathy in reproductive-aged women and has a vast array of clinical manifestations. Common clinical presentations of the disorder include anovulatory infertility, menstrual disorders, cutaneous symptoms secondary to androgen excess, metabolic abnormalities and mental health issues. If the condition is left unaddressed or inadequately treated, long-term sequelae such as endometrial hyperplasia, diabetes mellitus and dyslipidemia may ensue, therefore it is imperative for clinicians to address each component of the syndrome. When initial lifestyle changes and dietary modifications do not suffice or fail, pharmacologic therapy should be considered, and when deemed appropriate treatment should be initiated. This review describes the pharmacologic options available to combat the various sequelae commonly seen in women with polycystic ovarian syndrome. Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.

English

Powered by Koha